# A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

> **NCT03398655** · PHASE3 · COMPLETED · sponsor: **Vascular Biogenics Ltd. operating as VBL Therapeutics** · enrollment: 408 (actual)

## Conditions studied

- Recurrent Platinum Resistant Ovarian Cancer

## Interventions

- **DRUG:** VB-111 + Paclitaxel
- **DRUG:** Placebo + Paclitaxel

## Key facts

- **NCT ID:** NCT03398655
- **Lead sponsor:** Vascular Biogenics Ltd. operating as VBL Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-19
- **Primary completion:** 2022-07-19
- **Final completion:** 2022-07-19
- **Target enrollment:** 408 (ACTUAL)
- **Last updated:** 2023-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03398655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03398655, "A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03398655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*